Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment

Table of Contents

Chapter 1 BACKGROUND AND SCIENTIFIC OVERVIEW: ANTIBODIES AND MONOCLONAL ANTIBODIES

• 1.1. What Is an Antibody?
• 1.2. What Is a Monoclonal Antibody

Chapter 2 CURRENT AND EMERGING TECHNOLOGIES: IMPROVING MONOCLONAL ANTIBODY DESIGN AND PRODUCTION

• 2.1. Key Breakthroughs in the First 30 Years of Monoclonal Antibody Production
  • Murine-Derived Monoclonal Antibodies
  • Chimeric Monoclonal Antibodies
  • Humanized Monoclonal Antibodies
  • Fully Human Monoclonal Antibodies
  • Antibody Fragments
  • Antibody Conjugates
• 2.2. Monoclonal Antibody Libraries and Display Technologies
  • Phage Display
    • Cambridge Antibody Technology
    • Dyax
    • Crucell
    • MorphoSys
    • Affitech
    • Biosite
    • Affimed Therapeutics
    • XOMA
  • Ribosome Display
    • Cambridge Antibody Technology
    • Discerna
  • Other Library-Based Technologies
    • Alexion Antibody Technologies
    • BioInvent International
    • MSM Protein Technologies
    • Vaccinex
    • Morphotek
• 2.3. Other Technologies for Designing Monoclonal Antibodies
  • Techniques for Improving Hybridoma Production
    • Abeome
  • New Technologies for Generating Animal-Derived Monoclonal Antibodies
    • GENOVAC
    • Epitomics
  • Humanization Technology
    • Abmaxis
    • EvoGenix
    • AERES Biomedical/Therapeutic Antibody Group
    • ImmunoGen
    • KaloBios Pharmaceuticals
    • PDL BioPharma
    • Massachusetts Institute of Technology
    • XOMA
  • Transgenic Mice
    • Amgen
    • Medarex
    • AVANIR Pharmaceuticals
    • XTL Biopharmaceuticals
    • Regeneron Pharmaceuticals
  • Human Hybridoma Technology
    • Morphotek
• 2.4. Alternative Antibody Formats
  • Antibody Fragments
    • Genmab
  • Synthetic Antibodies
    • Ablynx
    • Affibody
    • Domantis
    • Enzon Pharmaceuticals/Micromet
    • EvoGenix
    • Regeneron Pharmaceuticals
  • Bispecific Antibodies
    • Elusys Therapeutics
    • Micromet
    • TRION Pharma
    • Affimed Therapeutics
    • Pharmexa/Affitech
    • Biotechnol
  • Other Antibodies that Enhance Effector Function
    • BioWa
    • MacroGenics
    • TolerRx
    • University of Oslo
    • InNexus Biotechnology
    • Xencor
    • TeGenero
• 2.5. Antibody Conjugates
  • Antibody-Radioisotope Conjugates
    • Affibody
    • PBL Therapeutics
    • Triton BioSystems
  • Antibody-Drug Conjugates
    • HERMES Biosciences
    • Celldex Therapeutics
    • Scancell
    • Virexx Medical
  • Antibody-Toxin Conjugates
    • EvoGenix
• 2.6. Technologies for Improving Monoclonal Antibody Characteristics
  • Protein Engineering
    • Applied Molecular Evolution
    • EvoGenix
    • Verenium
    • Morphotek
    • MilleGen
    • PDL BioPharma
  • PEGylation
    • Enzon Pharmaceuticals/Nektar Therapeutics
    • Prolong Pharmaceuticals
    • Ambrx
    • Others
  • Alternatives to PEGylation
  • Glycosylation
    • GlycArt Biotechnology
    • GlycoFi
    • Glycotope
    • Neose Technologies
    • LFB
  • Alternative Modes of Administration
    • Altus Pharmaceuticals
    • Epic Therapeutics
• 2.7. Technologies for Improving Monoclonal Antibody Production
  • Increasing Yields in Mammalian Cultures
  • Transgenic Animals
  • Transgenic Plants

Chapter 3 MARKETED AND EMERGING MONOCLONAL ANTIBODIES: PRESENT AND FUTURE THERAPEUTICS

• 3.1. Approved Therapeutic Monoclonal Antibodies
  • Profiles of Therapeutic Monoclonal Antibodies Approved for Marketing
    • Orthoclone OKT3 (Muromonab-CD3) (1986)
    • ReoPro (Abciximab) (1994)
    • Rituxan (Rituximab) (1997)
    • Zenapax (Daclizumab) (1997)
    • Simulect (Basiliximab) (1998)
    • Synagis (Palivizumab) (1998)
    • Remicade (Infliximab) (1998)
    • Herceptin (Trastuzumab) (1998)
    • Mylotarg (Gemtuzumab Ozogamicin) (2000)
    • Campath (Alemtuzumab) (2001)
    • Zevalin (Ibritumomab Tiuxetan) (2002)
    • Humira (Adalimumab) (2002)
    • Xolair (Omalizumab) (2003)
    • Bexxar (Tositumomab) (2003)
    • Raptiva (Efalizumab) (2003)
    • Erbitux (Cetuximab) (2004)
    • Avastin (Bevacizumab) (2004)
    • Tysabri (Natalizumab) (2006)
    • Lucentis (Ranibizumab) (2006)
    • Vectibix (Panitumumab) (2006)
    • Soliris (Eculizumab) (2007)
• 3.2. Monoclonal Antibodies in Development for Cancer
  • Unconjugated Monoclonal Antibodies for Cancer
    • Genmab
    • Medarex
    • Biogen Idec
    • Genentech
    • Human Genome Sciences
    • Wilex
    • Immunomedics
    • Regeneron Pharmaceuticals
    • ImClone Systems
    • Antisoma
    • Micromet
    • MedImmune
    • GPC Biotech
    • ARIUS Research
    • AVEO Pharmaceuticals
    • Lpath
    • Northwest Biotherapeutics
  • Anti-idiotype Antibodies for Cancer
    • Menarini Group
    • Onyvax
  • Conjugated Monoclonal Antibodies for Cancer
    • Viventia Biotech
    • Amgen
    • Active Biotech
    • Antisoma
    • ImmunoGen
    • Immunomedics
    • Cambridge Antibody Technology
    • Seattle Genetics
    • Merck Serono
    • CuraGen
    • Celldex Therapeutics
• 3.3. Monoclonal Antibodies in Development for Immunological Diseases
  • UCB
  • Regeneron Pharmaceuticals
  • Centocor
  • Human Genome Sciences
  • Zymogenetics
  • Amgen
  • Biogen Idec/Genentech
  • Cambridge Antibody Technology
  • Genmab
  • MedImmune
  • Millennium Pharmaceuticals
  • NovImmune
  • Medarex
  • Micromet
  • BioTie Therapies
  • CSL
  • Glenmark Pharmaceuticals
  • LigoCyte Pharmaceuticals
• 3.4. Monoclonal Antibodies in Development for Infectious Diseases
  • NeuTec Pharma
  • MedImmune
  • Human Genome Sciences
  • Progenix Pharmaceuticals
  • Medarex
  • XTL Biopharmaceuticals
  • Elusys Therapeutics
  • Genmab
  • AVANIR Pharmaceuticals
• 3.5. Monoclonal Antibodies in Development for Cardiovascular Diseases
  • Ablynx
  • ThromboGenics/BioInvent International
  • Affimed Therapeutics
  • Lexicon Pharmaceuticals
• 3.6. Other Therapeutic Antibodies in Development
  • Amgen
  • Elan/Wyeth
  • Rinat Neuroscience
  • Wyeth/Cambridge Antibody Technology

Chapter 4 BUSINESS AND STRATEGIC OUTLOOK: MARKET POTENTIAL FOR MONOCLONAL ANTIBODIES AND TRENDS IN THE FIELD

• 4.1. General Trends
• 4.2. The Market for Therapeutic Monoclonal Antibodies
  • Cancer: Solid Tumors
  • Cancer: Non-Hodgkin' s Lymphoma
  • Immune and Inflammatory Diseases
    • Transplant Rejection
    • Rheumatoid Arthritis
    • Crohn' s Disease
    • Psoriasis
    • Lupus
    • Multiple Sclerosis
    • Asthma
  • Other Emerging Markets
    • Age-Related Macular Degeneration
    • HIV
    • Alzheimer' s Disease

Appendix CHI INSIGHT PHARMA REPORTS MONOCLONAL ANTIBODIES SURVEY-JULY 2007

References

Company Index with Web Addresses